Which has preferable valuation and earnings, LIVN or CDRE?

Cadre has lower revenue, but higher earnings than LivaNova. Cadre is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 2.86 -$242.47M $1.95 37.11 Cadre $610.31M 2.10 $44.14M $0.89 33.60

Is LIVN or CDRE more profitable?

LivaNova has a net margin of 7.48% compared to Cadre's net margin of 5.80%. LivaNova's return on equity of 16.48% beat Cadre's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Cadre 5.80% 12.39% 5.08%

Does the media prefer LIVN or CDRE?

In the previous week, Cadre had 3 more articles in the media than LivaNova. MarketBeat recorded 6 mentions for Cadre and 3 mentions for LivaNova. Cadre's average media sentiment score of 0.61 beat LivaNova's score of 0.09 indicating that Cadre is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cadre 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, NVST or CDRE?

Envista has higher revenue and earnings than Cadre. Cadre is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Envista $2.72B 1.38 $47M $0.41 56.29 Cadre $610.31M 2.10 $44.14M $0.89 33.60

Is NVST or CDRE more profitable?

Cadre has a net margin of 5.80% compared to Envista's net margin of 2.41%. Cadre's return on equity of 12.39% beat Envista's return on equity. Company Net Margins Return on Equity Return on Assets Envista 2.41% 7.11% 3.91% Cadre 5.80% 12.39% 5.08%

Does the media refer more to NVST or CDRE?

In the previous week, Cadre had 5 more articles in the media than Envista. MarketBeat recorded 6 mentions for Cadre and 1 mentions for Envista. Cadre's average media sentiment score of 0.61 beat Envista's score of 0.50 indicating that Cadre is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Envista 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cadre 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IRTC or CDRE?

In the previous week, Cadre had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 6 mentions for Cadre and 4 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.24 beat Cadre's score of 0.61 indicating that iRhythm Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cadre 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, MMED or CDRE?

Cadre has lower revenue, but higher earnings than MiniMed Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiniMed Group $2.99B 1.34 N/A N/A N/A Cadre $610.31M 2.10 $44.14M $0.89 33.60

Does the media prefer MMED or CDRE?

In the previous week, MiniMed Group had 3 more articles in the media than Cadre. MarketBeat recorded 9 mentions for MiniMed Group and 6 mentions for Cadre. Cadre's average media sentiment score of 0.61 beat MiniMed Group's score of -0.23 indicating that Cadre is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cadre 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, SLNO or CDRE?

Cadre has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Soleno Therapeutics $285.01M 9.69 $20.89M $1.77 29.95 Cadre $610.31M 2.10 $44.14M $0.89 33.60

Cadre (CDRE) Competitors

$29.90 -0.11 (-0.37%)

Closing price 06/5/2026 03:59 PM Eastern

Extended Trading

$30.00 +0.10 (+0.33%)

As of 06/5/2026 04:25 PM Eastern

Compare

CDRE vs. LIVN, NVST, IRTC, MMED, and SLNO

Should you buy Cadre stock or one of its competitors? MarketBeat compares Cadre with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cadre include LivaNova (LIVN), Envista (NVST), iRhythm Technologies (IRTC), MiniMed Group (MMED), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry.

How does Cadre compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Cadre (NYSE:CDRE) are both medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

In the previous week, Cadre had 3 more articles in the media than LivaNova. MarketBeat recorded 6 mentions for Cadre and 3 mentions for LivaNova. Cadre's average media sentiment score of 0.61 beat LivaNova's score of 0.09 indicating that Cadre is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cadre	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.6% of LivaNova shares are held by institutional investors. Comparatively, 44.0% of Cadre shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 30.1% of Cadre shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

LivaNova has a net margin of 7.48% compared to Cadre's net margin of 5.80%. LivaNova's return on equity of 16.48% beat Cadre's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Cadre	5.80%	12.39%	5.08%

LivaNova currently has a consensus target price of $79.38, indicating a potential upside of 9.69%. Cadre has a consensus target price of $39.75, indicating a potential upside of 32.94%. Given Cadre's higher probable upside, analysts clearly believe Cadre is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cadre	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Cadre has lower revenue, but higher earnings than LivaNova. Cadre is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.86	-$242.47M	$1.95	37.11
Cadre	$610.31M	2.10	$44.14M	$0.89	33.60

LivaNova has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Cadre has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

Summary

LivaNova beats Cadre on 10 of the 17 factors compared between the two stocks.

How does Cadre compare to Envista?

Envista (NYSE:NVST) and Cadre (NYSE:CDRE) are both medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

In the previous week, Cadre had 5 more articles in the media than Envista. MarketBeat recorded 6 mentions for Cadre and 1 mentions for Envista. Cadre's average media sentiment score of 0.61 beat Envista's score of 0.50 indicating that Cadre is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envista	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cadre	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Envista presently has a consensus target price of $28.83, indicating a potential upside of 24.94%. Cadre has a consensus target price of $39.75, indicating a potential upside of 32.94%. Given Cadre's stronger consensus rating and higher possible upside, analysts plainly believe Cadre is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cadre	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

44.0% of Cadre shares are owned by institutional investors. 1.0% of Envista shares are owned by company insiders. Comparatively, 30.1% of Cadre shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Envista has higher revenue and earnings than Cadre. Cadre is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.38	$47M	$0.41	56.29
Cadre	$610.31M	2.10	$44.14M	$0.89	33.60

Envista has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Cadre has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Cadre has a net margin of 5.80% compared to Envista's net margin of 2.41%. Cadre's return on equity of 12.39% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
Cadre	5.80%	12.39%	5.08%

Summary

Cadre beats Envista on 13 of the 17 factors compared between the two stocks.

How does Cadre compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Cadre (NYSE:CDRE) are both medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

44.0% of Cadre shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by company insiders. Comparatively, 30.1% of Cadre shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cadre has a net margin of 5.80% compared to iRhythm Technologies' net margin of -3.53%. Cadre's return on equity of 12.39% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Cadre	5.80%	12.39%	5.08%

iRhythm Technologies has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Cadre has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

In the previous week, Cadre had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 6 mentions for Cadre and 4 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.24 beat Cadre's score of 0.61 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cadre	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cadre has lower revenue, but higher earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$787.85M	4.51	-$44.55M	-$0.86	N/A
Cadre	$610.31M	2.10	$44.14M	$0.89	33.60

iRhythm Technologies presently has a consensus price target of $189.69, indicating a potential upside of 75.46%. Cadre has a consensus price target of $39.75, indicating a potential upside of 32.94%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe iRhythm Technologies is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Cadre	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

Cadre beats iRhythm Technologies on 10 of the 17 factors compared between the two stocks.

How does Cadre compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Cadre (NYSE:CDRE) are both medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

19.7% of MiniMed Group shares are held by institutional investors. Comparatively, 44.0% of Cadre shares are held by institutional investors. 2.2% of MiniMed Group shares are held by company insiders. Comparatively, 30.1% of Cadre shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MiniMed Group presently has a consensus price target of $21.33, suggesting a potential upside of 49.92%. Cadre has a consensus price target of $39.75, suggesting a potential upside of 32.94%. Given MiniMed Group's stronger consensus rating and higher possible upside, research analysts plainly believe MiniMed Group is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Cadre	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Cadre has a net margin of 5.80% compared to MiniMed Group's net margin of 0.00%. Cadre's return on equity of 12.39% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Cadre	5.80%	12.39%	5.08%

In the previous week, MiniMed Group had 3 more articles in the media than Cadre. MarketBeat recorded 9 mentions for MiniMed Group and 6 mentions for Cadre. Cadre's average media sentiment score of 0.61 beat MiniMed Group's score of -0.23 indicating that Cadre is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cadre	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cadre has lower revenue, but higher earnings than MiniMed Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$2.99B	1.34	N/A	N/A	N/A
Cadre	$610.31M	2.10	$44.14M	$0.89	33.60

Summary

Cadre beats MiniMed Group on 8 of the 13 factors compared between the two stocks.

How does Cadre compare to Soleno Therapeutics?

Soleno Therapeutics (NASDAQ:SLNO) and Cadre (NYSE:CDRE) are both medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 44.0% of Cadre shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by insiders. Comparatively, 30.1% of Cadre shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Soleno Therapeutics currently has a consensus target price of $76.67, suggesting a potential upside of 44.63%. Cadre has a consensus target price of $39.75, suggesting a potential upside of 32.94%. Given Soleno Therapeutics' higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08
Cadre	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Cadre has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95
Cadre	$610.31M	2.10	$44.14M	$0.89	33.60

Soleno Therapeutics has a beta of -2.22, suggesting that its stock price is 322% less volatile than the broader market. Comparatively, Cadre has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Soleno Therapeutics has a net margin of 33.70% compared to Cadre's net margin of 5.80%. Soleno Therapeutics' return on equity of 22.85% beat Cadre's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	33.70%	22.85%	18.25%
Cadre	5.80%	12.39%	5.08%

In the previous week, Cadre had 6 more articles in the media than Soleno Therapeutics. MarketBeat recorded 6 mentions for Cadre and 0 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 0.94 beat Cadre's score of 0.61 indicating that Soleno Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Soleno Therapeutics	Positive
Cadre	Positive

Summary

Soleno Therapeutics and Cadre tied by winning 8 of the 16 factors compared between the two stocks.

Get Cadre News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDRE vs. The Competition

Export

Metric	Cadre	PROTECTION Industry	Industrials Sector	NYSE Exchange
Market Cap	$1.28B	$3.37B	$9.41B	$23.05B
Dividend Yield	1.33%	2.56%	3.54%	4.09%
P/E Ratio	33.60	19.42	24.99	30.25
Price / Sales	2.10	4.96	5,034.48	22.80
Price / Cash	18.66	26.79	27.37	18.46
Price / Book	3.82	3.55	4.79	4.62
Net Income	$44.14M	$106.44M	$793.53M	$1.07B
7 Day Performance	-2.54%	-7.76%	1.95%	-1.82%
1 Month Performance	0.39%	-8.24%	2,655.28%	-1.22%
1 Year Performance	-13.39%	-20.17%	29.84%	21.20%

Cadre Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDRE Cadre	4.6299 of 5 stars	$29.90 -0.4%	$39.75 +32.9%	-13.4%	$1.28B	$610.31M	33.60	2,533
LIVN LivaNova	2.7181 of 5 stars	$75.42 +2.2%	$79.38 +5.2%	+57.5%	$4.14B	$1.39B	38.68	3,300
NVST Envista	3.0613 of 5 stars	$23.52 +0.4%	$28.83 +22.6%	+22.9%	$3.83B	$2.72B	57.37	12,000
IRTC iRhythm Technologies	4.2886 of 5 stars	$114.45 -1.8%	$191.85 +67.6%	-26.3%	$3.76B	$747.14M	N/A	2,400
MMED MiniMed Group	3.4335 of 5 stars	$11.18 -5.8%	$21.67 +93.8%	N/A	$3.14B	$2.99B	N/A	8,000	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CDRE) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cadre (CDRE) Competitors